Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
News and press releases about Insmed Incorporated (INSM) provide insight into the company’s progress as a global biopharmaceutical organization focused on serious and rare diseases. Insmed regularly issues updates on its commercial performance, clinical trial milestones, regulatory decisions, and corporate initiatives across its respiratory, immunology & inflammation, and neuro & other rare disease programs.
Recent news has highlighted key events such as U.S. Food and Drug Administration approval of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, European Commission approval of BRINSUPRI for specified NCFB patients in the European Union, and detailed business updates around the commercial launch of BRINSUPRI and continued global growth of ARIKAYCE (amikacin liposome inhalation suspension). Investors can also follow announcements on the advancement of TPIP (treprostinil palmitil inhalation powder) into Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and other pulmonary indications.
Insmed’s news flow also covers clinical data readouts from studies such as ASPEN and WILLOW in NCFB, the BiRCh and CEDAR trials evaluating brensocatib in additional neutrophil-mediated diseases, and early-stage developments in gene therapy programs INS1201, INS1202, and INS1203. Corporate communications include financial results, conference presentations at major healthcare and respiratory congresses, and updates on acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory conditions.
For followers of INSM stock, this news page offers a centralized view of Insmed’s ongoing commercial execution, regulatory interactions, and pipeline evolution. Regular updates help track how the company’s therapies and investigational candidates are progressing through development and reaching patient populations worldwide.
Insmed (Nasdaq: INSM) reported preliminary unaudited full-year 2025 net product revenues of $606.4M (up 67% vs. 2024), driven by ARIKAYCE $433.8M and BRINSUPRI $172.7M. BRINSUPRI generated approximately $144.6M in its first full quarter. The company received European approval for BRINSUPRI and plans EU, UK, and Japan launches in 2026. Insmed expects 2026 ARIKAYCE revenue of $450M–$470M, announced key Phase 3 and Phase 2 readout timelines for ENCORE (Mar/Apr 2026) and CEDAR (Q2 2026), initiated PALM-ILD in Q4 2025, and acquired INS1148 in Dec 2025.
Insmed (Nasdaq: INSM) said management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026 at 3:00 p.m. PT / 6:00 p.m. ET. The presentation will be webcast live and available via the company’s investor relations website. Webcasts will be archived for 30 days after the live event.
Insmed (Nasdaq: INSM) announced on December 17, 2025 that the Phase 2b BiRCh study of brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg arms, and Insmed has discontinued the CRSsNP program effective immediately.
Topline placebo-adjusted least-squares means for 28-day average sTSS at Week 24 were placebo -2.44, brensocatib 10 mg -2.21, and brensocatib 40 mg -2.33. Safety was consistent with prior studies with no new signals. The company also acquired INS1148, a Phase 2–ready monoclonal antibody targeting SCF248, and plans initial development in interstitial lung disease and moderate-to-severe asthma.
Insmed (Nasdaq: INSM) will present seven abstracts at the European Respiratory Society (ERS) 2025 Congress, Sept 27–Oct 1, 2025, in Amsterdam.
Key highlights include data from a Phase 2b study of treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH) featured in the Congress's late‑breaking ALERT session, and three prespecified subgroup analyses from the Phase 3 ASPEN trial evaluating brensocatib, including efficacy and safety data in Japanese patients with non‑cystic fibrosis bronchiectasis (NCFB).
Presentations span an oral Elicium session, ALERT clinical trials session, and multiple poster sessions with specified presenters and scheduled times during Sept 28–30, 2025.
Insmed (Nasdaq: INSM) granted inducement awards to 92 new employees under its 2025 Inducement Plan to meet Nasdaq Listing Rule 5635(c)(4).
On November 28, 2025 the company issued 44,273 restricted stock units and options to purchase an aggregate of 2,490 shares at an exercise price of $207.77 per share (the Nasdaq closing price on the grant date).
The restricted stock units vest over four years with 25% vesting each anniversary of the first day of the month after the grant. Options have a 10-year term and a four-year vesting schedule: 25% at the first anniversary and 12.5% every six months thereafter, subject to continued service.
Insmed (Nasdaq: INSM) announced that the European Commission approved BRINSUPRI (brensocatib) 25 mg on November 18, 2025, as the first and only treatment for non-cystic fibrosis bronchiectasis (NCFB) in the EU for patients 12+ with ≥2 exacerbations in the prior 12 months.
Approval was granted after EMA accelerated assessment and is supported by Phase 3 ASPEN and Phase 2 WILLOW data showing a 19.4% reduction in annual exacerbation rate and statistically smaller FEV1 decline at week 52. EU access efforts begin in early 2026; U.K. and Japan reviews are ongoing.
Insmed (Nasdaq: INSM) held its fourth annual Global Day of Good on November 13, 2025, mobilizing more than 1,200 employees across the U.S., Europe, and Japan for simultaneous volunteer activities.
Teams supported health, education, and human services through meal-packing, care packages for children with serious diseases, STEM and hygiene kits, book translation, and outdoor space restoration. The company offers year-round volunteer programs, matching gifts, and paid volunteer time.
Insmed (Nasdaq: INSM) announced management will present at two investor conferences in November and December 2025: the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 8:30 a.m. GT / 3:30 a.m. ET, and the Evercore 8th Annual Healthcare Conference in Coral Gables, Florida on Tuesday, December 2, 2025 at 11:15 a.m. ET.
Both presentations will be webcast live and archived for 30 days on Insmed's investor relations website at www.insmed.com.
Insmed (Nasdaq: INSM) reported third-quarter 2025 results and a business update on October 30, 2025. Total revenue was $142.3 million in Q3 2025, driven by ARIKAYCE $114.3M (+22% YoY) and BRINSUPRI $28.1M following FDA approval and U.S. launch. The company raised full-year ARIKAYCE guidance to $420M–$430M (15%–18% YoY growth).
R&D and SG&A each were $186.4M in Q3, and Insmed reported a net loss of $370.0M (−$1.75/share). Cash and marketable securities totaled about $1.7B as of Sept 30, 2025. Key clinical catalysts are expected through 2026 across ARIKAYCE, brensocatib, and TPIP programs.
Insmed (Nasdaq: INSM) ranked No. 1 on Science's 2025 Top Biopharma Employers list, marking a record fifth consecutive year at the top, announced Oct. 23, 2025. The ranking is based on about 5,500 survey responses, primarily from North America (66%), Europe (20%), and Asia/Pacific Rim (9%). The company linked the recognition to a people-first culture and cited recent clinical successes and regulatory milestones as drivers of growth. Insmed highlighted strengths in corporate image, financial prowess, leadership, work culture, and intellectual challenge. More details and rankings are available on the publisher's feature and Insmed's culture page.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
